• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug and Therapeutics Bulletin >Teriparatide for postmenopausal osteoporosis
【24h】

Teriparatide for postmenopausal osteoporosis

机译：特立帕肽治疗绝经后骨质疏松

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Teriparatide (Forsteo - Eli Lilly) is the first parathyroid hormone derivative to be licensed for the treatment of women with postmenopausal osteoporosis. It is described as a "bone-formation agent", in contrast to established treatments, such as bisphosphonates, raloxifene, calcitriol and calcitonin, which reduce bone resorption. Here we consider whether teriparatide offers any worthwhile advantages over these other options. Bone undergoes continual remodelling through resorption by osteoclasts and formation of new bone by osteoblasts. Excessive loss of bone, as can occur following the menopause, may result in osteoporosis with a consequent increase in bone fragility and fracture risk. One key factor in the remodelling ofbone is parathyroid hormone, the principal regulator of calcium homeostasis. This hormone is released by the parathyroid glands in response to a low serum concentration of calcium. Its effects include increases in bone resorption, in renal tubular reabsorption of calcium, and in absorption of calcium and phosphate from the intestine. Sustained hypersecretion of parathyroid hormone leads to bone loss, particularly in cortical bone. However, daily administration of exogenous parathyroid hormone appears to have an anabolic effect that results in increased bone formation and improved bone microarchitecture.
机译：特立帕肽（Forsteo-Eli Lilly）是第一种被许可用于治疗绝经后骨质疏松症妇女的甲状旁腺激素衍生物。与诸如双膦酸盐，雷洛昔芬，骨化三醇和降钙素等已确立的减少骨吸收的治疗方法相反，它被描述为“骨形成剂”。在这里，我们考虑与其他选择相比，teriparatide是否具有任何有价值的优势。骨通过破骨细胞吸收和成骨细胞形成新骨而经历持续的重塑。更年期后可能发生的骨量过多损失可能会导致骨质疏松症，从而增加骨脆性和骨折风险。骨重塑的关键因素之一是甲状旁腺激素，它是钙稳态的主要调节因子。甲状旁腺会释放这种激素，以响应血清中钙的低浓度。它的作用包括增加骨吸收，增加肾小管对钙的吸收以及从肠吸收钙和磷酸盐。甲状旁腺激素持续过度分泌会导致骨质流失，尤其是在皮质骨中。然而，每天施用外源性甲状旁腺激素似乎具有合成代谢作用，导致增加的骨形成和改善的骨微结构。

著录项

  • 来源
    《Drug and Therapeutics Bulletin》 |2004年第12期|p.93-95|共3页
  • 作者

  • 作者单位
  • 收录信息 美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号